Vp Ww Medical

**Working with Us**
Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams rich in diversity. Take your career farther than you thought possible.

Head of WWHM Portfolio Strategy & Hematology Oncology Early Assets Biomarkers.**

**ROLE TITLE: VP WW Medical - Head of Portfolio Strategy Biomarkers & Early Assets Hematology & Oncology**

**HIRING MANAGER: Ridwaan Jhetam**

**LOCATION: Boudry, Switzerland / Summit, NJ**

**ROLE SUMMARY**

**Head of WWHM Portfolio Strategy, Biomarkers & Hematology & Oncology Early Assets.**

will lead a team to provide strategic medical input across the Portfolio to maximize health outcomes, clinical adoption and patient access across for BMS Assets across Hematology, Cell Therapies and early assets across Hematology & Oncology Therapy areas.

This is a senior medical leadership role reporting to the WW Medical Head of Hematology and will be a member of the WW Hematology & WW Oncology Medical Leadership Teams.

**RESPONSIBILITIES**
- Collaboration with Discovery, Early Development, Translational Research, Early Transition Assets to support optimal execution of personalized care and biomarker/diagnostic strategy for priority programs and ensure proper understanding and communication thereof both internally and externally.
- Lead the creation of an early integrated evidence plan that will differentiate the endpoints and outcomes for clinical trials and real-world evidence generation that are meaningful for physicians to change clinical practice, maximize patient access and outcomes.
- Shape Portfolio strategy, IEPs and CCF plans beyond regulatory requirements for local unmet needs and standard of care.
- Drive cross functional shaping for programs across the hematology & Oncology portfolio as they advance from discovery research through REDOC/ governance milestones.
- Lead understanding of clinical practice, unmet need, guidelines, and patient journey in the different therapeutic areas, establishing strong early Medical Affairs plans.
- Provide Priority new program strategic assessments, so the most transformational assets are prioritized.
- Key input to define the optimal target product profile (TPP) for any new or early-stage assets for transformational impact for patients.
- Function as a key member in discussions of BD/in-licensing and out-licensing of assets, collaborating closely with the business development team.
- Support of R&D, through the drug development process; and evaluation of business development and pipeline opportunities.
- Ensure deep local and stakeholder insights to inform shaping of pipeline assets.
- Lead and coach members of the Early Asset Medical Team.
- As a member of the WW Heme &oncology Medical Affairs Leadership team, contribute to leadership of the overall and broader medical roadmap
- Establish robust portfolio cross-asset medical strategy to maximize life cycle management with emphasis on maximizing launch and patient access to Hematology and Cell Therapies, partnering with disease area heads and key Market Heads
- Partner with MEG and GDD, GDO, HEOR and Disease Area Heads, to portfolio level evidence generation strategy for Hematology and Cell Therapies leading to optimal prioritization and earliest maximization and Life Cycle Management of our assets.
- Partner across the portfolio with Markets and Disease Area leads, and MEG to align on priorities related to evidence generation strategy to appropriately inform and support prioritization of local evidence generation studies and asset related strategies and projects.
- Appropriately collaborate with and engage Market Access/Health Economics Outcomes Research (HEOR) to inform regional data gaps and mitigation strategies.
- Integrate Global Development Operations (GDO) and Regional Clinical Operations (RCO) in strategy definition and feasibility for successful execution of priority Oncology & Hematology/ Cell Therapy products.
- Partner with Disease Area leads, Strategic collaborations and GDD and GDO to identify and facilitate the establishment of research collaborations with academic, governmental and research and treatment centres in line with WW Medical, Major Markets and/or Intercon, and country priorities, including pre-clinical, translational, clinical, RWE and digital health programs.
- Drive early medical expert and scientific engagement in key strategic countries.
- Ensure strong Scientific Communications plans are being executed in the different therapeutic areas
- Partner with Disease Area leads and IT partners; analytics te